A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
Primary Purpose
Post-Traumatic Stress Disorder
Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BI 1358894
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Post-Traumatic Stress Disorder
Eligibility Criteria
Inclusion Criteria:
- Established diagnosis of Post-Traumatic Stress Disorder (PTSD) corresponding to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
- Time since index event according to Life Events Checklist / Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Criterion A at least 3 months before screening visit
- PTSD must be the clinically pre-dominant disorder, as per investigator´s judgement. Other comorbid psychiatric disorders are allowed, unless specifically excluded in the exclusion criteria
- A total severity score of ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) at the screening visit
- Moderate to severe PTSD confirmed by CAPS-5 range ≥ 30 confirmed at screening visit
- Male or female patients, 18 to 65 years of age, both inclusively at the time of informed consent
- Women who are of child-bearing potential (WOCBP) must be able and willing to use two methods of contraception, as confirmed by the investigator, which include one highly effective method of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1%, plus one additional barrier method
- Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
Exclusion Criteria:
- Corresponding to DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder, delusional disorder, brief psychotic disorder or any other psychotic disorder as well as Major Depressive Disorder (MDD) with psychotic features as assessed by the Mini-International Neuropsychiatric Interview (MINI) at the time of screening
- Any psychiatric or non-psychiatric medical condition likely to negatively impact trial participation as per the judgement of the investigator
- Acute stress disorder or significant traumatic event within 3 months prior to the screening visit
- Use of stimulant medications within 3 months prior to the screening visit (Attention Deficit Hyperactivity Disorder (ADHD) diagnosis alone is not exclusionary)
- Severe traumatic brain injury (life-time) or moderate traumatic brain injury within the last 2 years prior to screening visit or 3 months for mild traumatic brain injury, based on the Ohio State University Traumatic Brain Injury (TBI) Identification Method Short Form. Or history of traumatic brain injury that would impact ability to complete trial assessments or procedures according to investigator.
- Current treatment with trauma focused therapy (i.e. Cognitive Processing Therapy (CPT), Prolonged Exposure Therapy (PE), Eye Movement Desensitization and Reprocessing (EMDR)). A psychotherapy in type, intensity and/or frequency other than trauma focused therapy is allowed if stable within the last 8 weeks prior to screening and not anticipated to change during the entire course of the trial. Long-term psychotherapy is permitted as long as patients are not in an exposure phase during the trial.
- Diagnosis of a current moderate or severe alcohol use disorder according to MINI within 3 months prior to screening visit (mild alcohol use disorder (AUD) and patients in early remission = criterion not met for between 3 & 12 months are allowed) Further exclusion criteria apply
Sites / Locations
- Woodland International Research Group, Inc.
- Behavioral Research Specialists, LLC
- ASCLEPES Research Centers, P.C. dba Alliance Research
- CalNeuro Research Group Inc.
- Artemis Institute for Clinical Research
- Artemis Institute for Clinical Research, LLC
- Clinical Innovations Inc.
- California Neuroscience Research
- Collaborative Neuroscience Research, LLC
- Mountain Mind. LLC
- CNS Clinical Research - Coral Springs
- Innovative Clinical Research
- Miami Dade Medical Research Institute, LLC
- Medical Research Group of Central Florida
- Elixia PHC, LLC
- Institute for Advanced Medical Research
- Emory University
- American Medical Research
- University of Chicago
- Pharmasite Research, Incorporated
- Boston Clinical Trials
- Sisu BHR, LLC
- NeuroBehavioral Medicine Group
- Hassman Research Institute
- Center For Emotional Fitness
- Princeton Medical Institute
- Neurobehavioral Research, Inc.
- Insight Clinical Trials
- North Star Medical Research, LLC
- The University of Texas at Austin
- FutureSearch Trials of Dallas, LP
- Relaro Medical Trials, LLC
- Baylor College of Medicine
- Red Oak Psychiatry Associates, PA
- Audie L. Murphy VA Hospital
- Grayline Research Center
- Salem VA Medical Center
- Clincal Hospital Centre Rijeka
- Polyclinic Neuron
- Solmed Clinic
- Psychiatric Hospital 'Sveti Ivan'
- University Psychiatric Hospital Vrapce
- Eira Medical Centre
- Oulu Mentalcare Oy
- Mehiläinen Tampere
- Universitätsklinikum Aachen, AöR
- Zentralinstitut für seelische Gesundheit
- Klinikum der Universität München - Campus Innenstadt
- Universitätsklinikum Tübingen
- Lev Hasharon Mental Health Center
- The Chaim Sheba Medical Center Tel HaShomer
- Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
- Hospital Aranda de la Parra
- CIT-Neuropsique S.C
- BIND Investigaciones S.C.
- MlynowaMed
- In-Vivo Sp. Z o.o.
- MTZ Clinical Research Powered by Pratia
- Psykiatri Södra Stockholm
- Psykiatri Affektiva sjukdomar
- Psykiatri Sydväst Stockholm
- Akademiska sjukhuset
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
BI 1358894
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in Clinician-Administered Post-Traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) total severity score
CAPS-5 is a 30-item structured interview. In addition to assessing the 20 DSM-5 PTSD symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Each of the 20 symptom items is rated on a 5-point severity rating scale ranging from 0 (absent) to 4 (extreme/incapacitating) CAPS-5 total symptom severity score is yield by summing individual item scores. The total severity score ranges from 0 to 80 with higher scores indicating higher symptom severity.
Secondary Outcome Measures
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Response defined as ≥30% CAPS-5 reduction from baseline
CAPS-5 is a 30-item structured interview. In addition to assessing the 20 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Post-Traumatic Stress Disorder (PTSD) symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Each of the 20 symptom items is rated on a 5-point severity rating scale ranging from 0 (absent) to 4 (extreme/incapacitating) CAPS-5 total symptom severity score is yield by summing individual item scores. The total severity score ranges from 0 to 80 with higher scores indicating higher symptom severity.
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Response defined as ≥50% CAPS-5 reduction from baseline
CAPS-5 is a 30-item structured interview. In addition to assessing the 20 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Post-Traumatic Stress Disorder (PTSD) symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Each of the 20 symptom items is rated on a 5-point severity rating scale ranging from 0 (absent) to 4 (extreme/incapacitating) CAPS-5 total symptom severity score is yield by summing individual item scores. The total severity score ranges from 0 to 80 with higher scores indicating higher symptom severity.
Change from baseline on the PTSD Checklist for DSM-5 (PCL-5) total score
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item patient-reported assessment designed to measure the presence and severity of PTSD symptoms. The PCL-5 is intended to assess patient symptoms in the past month. Each item is rated on a fivepoint Likert scale, from 0 (not at all) to 4 (extremely). A total severity score can be yield by summing up individual item scores, and ranges from 0 to 80 with higher scores indicating higher severity.
Full Information
NCT ID
NCT05103657
First Posted
October 21, 2021
Last Updated
October 16, 2023
Sponsor
Boehringer Ingelheim
1. Study Identification
Unique Protocol Identification Number
NCT05103657
Brief Title
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
Official Title
A Phase II, 8-week-treatment, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy, Tolerability and Safety of Orally Administered BI 1358894 in Patients With Post-Traumatic Stress Disorder (PTSD)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 7, 2021 (Actual)
Primary Completion Date
October 6, 2023 (Anticipated)
Study Completion Date
November 3, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is open to people aged 18 to 65 who have post-traumatic stress disorder. The purpose of this study is to find out whether a medicine called BI 1358894 improves symptoms in people with post-traumatic stress disorder.
Participants are put into 2 groups randomly, which means by chance. Participants take BI 1358894 or placebo as tablets every day for 2 months. Placebo tablets look like BI 1358894 tablets but do not contain any medicine.
Participants are in the study for about 3 months. During this time, they visit the study site about 8 times and get about 4 phone calls from the trial staff. During the study, participants answer questions in interviews and complete questionnaires so the doctors can check whether their symptoms change.
The doctors also regularly check participants' health and take note of any unwanted effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-Traumatic Stress Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
318 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BI 1358894
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
BI 1358894
Intervention Description
BI 1358894
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in Clinician-Administered Post-Traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) total severity score
Description
CAPS-5 is a 30-item structured interview. In addition to assessing the 20 DSM-5 PTSD symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Each of the 20 symptom items is rated on a 5-point severity rating scale ranging from 0 (absent) to 4 (extreme/incapacitating) CAPS-5 total symptom severity score is yield by summing individual item scores. The total severity score ranges from 0 to 80 with higher scores indicating higher symptom severity.
Time Frame
At baseline and at week 8
Secondary Outcome Measure Information:
Title
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Response defined as ≥30% CAPS-5 reduction from baseline
Description
CAPS-5 is a 30-item structured interview. In addition to assessing the 20 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Post-Traumatic Stress Disorder (PTSD) symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Each of the 20 symptom items is rated on a 5-point severity rating scale ranging from 0 (absent) to 4 (extreme/incapacitating) CAPS-5 total symptom severity score is yield by summing individual item scores. The total severity score ranges from 0 to 80 with higher scores indicating higher symptom severity.
Time Frame
At baseline and at week 8
Title
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Response defined as ≥50% CAPS-5 reduction from baseline
Description
CAPS-5 is a 30-item structured interview. In addition to assessing the 20 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Post-Traumatic Stress Disorder (PTSD) symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Each of the 20 symptom items is rated on a 5-point severity rating scale ranging from 0 (absent) to 4 (extreme/incapacitating) CAPS-5 total symptom severity score is yield by summing individual item scores. The total severity score ranges from 0 to 80 with higher scores indicating higher symptom severity.
Time Frame
At baseline and at week 8
Title
Change from baseline on the PTSD Checklist for DSM-5 (PCL-5) total score
Description
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item patient-reported assessment designed to measure the presence and severity of PTSD symptoms. The PCL-5 is intended to assess patient symptoms in the past month. Each item is rated on a fivepoint Likert scale, from 0 (not at all) to 4 (extremely). A total severity score can be yield by summing up individual item scores, and ranges from 0 to 80 with higher scores indicating higher severity.
Time Frame
At baseline and at week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Established diagnosis of Post-Traumatic Stress Disorder (PTSD) corresponding to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
Time since index event according to Life Events Checklist / Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Criterion A at least 3 months before screening visit
PTSD must be the clinically pre-dominant disorder, as per investigator´s judgement. Other comorbid psychiatric disorders are allowed, unless specifically excluded in the exclusion criteria
A total severity score of ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) at the screening visit
Moderate to severe PTSD confirmed by CAPS-5 range ≥ 30 confirmed at screening visit
Male or female patients, 18 to 65 years of age, both inclusively at the time of informed consent
Women who are of child-bearing potential (WOCBP) must be able and willing to use two methods of contraception, as confirmed by the investigator, which include one highly effective method of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1%, plus one additional barrier method
Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
Exclusion Criteria:
Corresponding to DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder, delusional disorder, brief psychotic disorder or any other psychotic disorder as well as Major Depressive Disorder (MDD) with psychotic features as assessed by the Mini-International Neuropsychiatric Interview (MINI) at the time of screening
Any psychiatric or non-psychiatric medical condition likely to negatively impact trial participation as per the judgement of the investigator
Acute stress disorder or significant traumatic event within 3 months prior to the screening visit
Use of stimulant medications within 3 months prior to the screening visit (Attention Deficit Hyperactivity Disorder (ADHD) diagnosis alone is not exclusionary)
Severe traumatic brain injury (life-time) or moderate traumatic brain injury within the last 2 years prior to screening visit or 3 months for mild traumatic brain injury, based on the Ohio State University Traumatic Brain Injury (TBI) Identification Method Short Form. Or history of traumatic brain injury that would impact ability to complete trial assessments or procedures according to investigator.
Current treatment with trauma focused therapy (i.e. Cognitive Processing Therapy (CPT), Prolonged Exposure Therapy (PE), Eye Movement Desensitization and Reprocessing (EMDR)). A psychotherapy in type, intensity and/or frequency other than trauma focused therapy is allowed if stable within the last 8 weeks prior to screening and not anticipated to change during the entire course of the trial. Long-term psychotherapy is permitted as long as patients are not in an exposure phase during the trial.
Diagnosis of a current moderate or severe alcohol use disorder according to MINI within 3 months prior to screening visit (mild alcohol use disorder (AUD) and patients in early remission = criterion not met for between 3 & 12 months are allowed) Further exclusion criteria apply
Facility Information:
Facility Name
Woodland International Research Group, Inc.
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72211
Country
United States
Facility Name
Behavioral Research Specialists, LLC
City
Glendale
State/Province
California
ZIP/Postal Code
91206
Country
United States
Facility Name
ASCLEPES Research Centers, P.C. dba Alliance Research
City
Long Beach
State/Province
California
ZIP/Postal Code
90807
Country
United States
Facility Name
CalNeuro Research Group Inc.
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Artemis Institute for Clinical Research
City
Riverside
State/Province
California
ZIP/Postal Code
92503
Country
United States
Facility Name
Artemis Institute for Clinical Research, LLC
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Clinical Innovations Inc.
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Facility Name
California Neuroscience Research
City
Sherman Oaks
State/Province
California
ZIP/Postal Code
91403
Country
United States
Facility Name
Collaborative Neuroscience Research, LLC
City
Torrance
State/Province
California
ZIP/Postal Code
90504
Country
United States
Facility Name
Mountain Mind. LLC
City
Denver
State/Province
Colorado
ZIP/Postal Code
80202
Country
United States
Facility Name
CNS Clinical Research - Coral Springs
City
Coral Springs
State/Province
Florida
ZIP/Postal Code
33067
Country
United States
Facility Name
Innovative Clinical Research
City
Lauderhill
State/Province
Florida
ZIP/Postal Code
33319
Country
United States
Facility Name
Miami Dade Medical Research Institute, LLC
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Medical Research Group of Central Florida
City
Orange City
State/Province
Florida
ZIP/Postal Code
32763
Country
United States
Facility Name
Elixia PHC, LLC
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33713
Country
United States
Facility Name
Institute for Advanced Medical Research
City
Alpharetta
State/Province
Georgia
ZIP/Postal Code
30022
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Facility Name
American Medical Research
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Pharmasite Research, Incorporated
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21208
Country
United States
Facility Name
Boston Clinical Trials
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02131
Country
United States
Facility Name
Sisu BHR, LLC
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01103
Country
United States
Facility Name
NeuroBehavioral Medicine Group
City
Bloomfield Hills
State/Province
Michigan
ZIP/Postal Code
48302
Country
United States
Facility Name
Hassman Research Institute
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Facility Name
Center For Emotional Fitness
City
Cherry Hill
State/Province
New Jersey
ZIP/Postal Code
08002
Country
United States
Facility Name
Princeton Medical Institute
City
Princeton
State/Province
New Jersey
ZIP/Postal Code
08540
Country
United States
Facility Name
Neurobehavioral Research, Inc.
City
Cedarhurst
State/Province
New York
ZIP/Postal Code
11516
Country
United States
Facility Name
Insight Clinical Trials
City
Beachwood
State/Province
Ohio
ZIP/Postal Code
44122
Country
United States
Facility Name
North Star Medical Research, LLC
City
Middleburg Heights
State/Province
Ohio
ZIP/Postal Code
44130
Country
United States
Facility Name
The University of Texas at Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78712
Country
United States
Facility Name
FutureSearch Trials of Dallas, LP
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Relaro Medical Trials, LLC
City
Dallas
State/Province
Texas
ZIP/Postal Code
75243
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Red Oak Psychiatry Associates, PA
City
Houston
State/Province
Texas
ZIP/Postal Code
77090
Country
United States
Facility Name
Audie L. Murphy VA Hospital
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Grayline Research Center
City
Wichita Falls
State/Province
Texas
ZIP/Postal Code
76309
Country
United States
Facility Name
Salem VA Medical Center
City
Salem
State/Province
Virginia
ZIP/Postal Code
24153
Country
United States
Facility Name
Clincal Hospital Centre Rijeka
City
Rijeka
ZIP/Postal Code
51 000
Country
Croatia
Facility Name
Polyclinic Neuron
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Solmed Clinic
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Psychiatric Hospital 'Sveti Ivan'
City
Zagreb
ZIP/Postal Code
10090
Country
Croatia
Facility Name
University Psychiatric Hospital Vrapce
City
Zagreb
ZIP/Postal Code
10090
Country
Croatia
Facility Name
Eira Medical Centre
City
Helsinki
ZIP/Postal Code
00150
Country
Finland
Facility Name
Oulu Mentalcare Oy
City
Oulu
ZIP/Postal Code
90100
Country
Finland
Facility Name
Mehiläinen Tampere
City
Tampere
ZIP/Postal Code
FI-33210
Country
Finland
Facility Name
Universitätsklinikum Aachen, AöR
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
Zentralinstitut für seelische Gesundheit
City
Mannheim
ZIP/Postal Code
68159
Country
Germany
Facility Name
Klinikum der Universität München - Campus Innenstadt
City
München
ZIP/Postal Code
80336
Country
Germany
Facility Name
Universitätsklinikum Tübingen
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Lev Hasharon Mental Health Center
City
Netania
ZIP/Postal Code
4250602
Country
Israel
Facility Name
The Chaim Sheba Medical Center Tel HaShomer
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Facility Name
Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
City
Culiacan
ZIP/Postal Code
80230
Country
Mexico
Facility Name
Hospital Aranda de la Parra
City
Leon
ZIP/Postal Code
37000
Country
Mexico
Facility Name
CIT-Neuropsique S.C
City
Monterrey
ZIP/Postal Code
64610
Country
Mexico
Facility Name
BIND Investigaciones S.C.
City
San Luis Potosi
ZIP/Postal Code
78213
Country
Mexico
Facility Name
MlynowaMed
City
Bialystok
ZIP/Postal Code
15-404
Country
Poland
Facility Name
In-Vivo Sp. Z o.o.
City
Bydgoszcz
ZIP/Postal Code
85-048
Country
Poland
Facility Name
MTZ Clinical Research Powered by Pratia
City
Warszawa
ZIP/Postal Code
02-172
Country
Poland
Facility Name
Psykiatri Södra Stockholm
City
Enskede
ZIP/Postal Code
122 31
Country
Sweden
Facility Name
Psykiatri Affektiva sjukdomar
City
Gothenburg
ZIP/Postal Code
416 50
Country
Sweden
Facility Name
Psykiatri Sydväst Stockholm
City
Huddinge/Stockholm
ZIP/Postal Code
141 86
Country
Sweden
Facility Name
Akademiska sjukhuset
City
Uppsala
ZIP/Postal Code
751 85
Country
Sweden
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.
IPD Sharing Time Frame
After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD Sharing Access Criteria
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
IPD Sharing URL
https://www.mystudywindow.com/msw/datasharing
Links:
URL
http://www.mystudywindow.com
Description
Related Info
Learn more about this trial
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
We'll reach out to this number within 24 hrs